• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Gracell Biotechnologies Inc.

    2/14/24 8:00:10 AM ET
    $GRCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRCL alert in real time by email
    SC 13G 1 g118245sc13g.htm

     

    CUSIP No. 38406L103 Page 1 of 6
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
     
    Gracell Biotechnologies Inc.
    (Name of Issuer)
     
    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
     
    38406L103 **
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **This is the CUSIP Number for the Issuer’s American Depositary Shares, which are traded on the Nasdaq Stock Market. There is no CUSIP Number for the Ordinary Shares. Each American Depositary Share represents five Ordinary Shares.

     

     

      
     

    CUSIP No. 38406L103 Page 2 of 6

     

    1.

    Names of Reporting Person

     

    I.R.S. Identification Nos. of Above Persons (entities only)

     

    Sio Capital Management, LLC

     

    20-4586565

    2.

    Check the Appropriate Box if a Member of a Group

     

     

    (a) ¨

    (b) ¨

    3.

    SEC Use Only

     

     
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially

    Owned by Each Reporting

    Person With1

    5.

    Sole Voting Power

     

    -0-
    6.

    Shared Voting Power

     

    25,007,900 (1)
    7.

    Sole Dispositive Power

     

    -0-
    8.

    Shared Dispositive Power

     

    25,007,900 (1)
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    25,007,900 (1)
    10.

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     

    See Item 4

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.2% (2)
    12. Type of Reporting Person IA
               

     

    (1) As of December 31, 2023, Sio Capital Management, LLC beneficially owned 25,007,900 Ordinary Shares, held as 5,001,580 American Depositary Shares (“ADSs”). Each ADS represents five Ordinary Shares.

     

    (2) Based on 482,861,887 Ordinary Shares issued and outstanding as of December 19, 2023, as reported in Exhibit 2.1 to the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on December 26, 2023.

     

      
     

    CUSIP No. 38406L103 Page 3 of 6

     

    Schedule 13G

     

    Item 1(a).Name of Issuer:

     

      Gracell Biotechnologies, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

     

    Building 12, Block B, Phase II

    Biobay Industrial Park, 218 Sangtian St. Suzhou Industrial Park

    People’s Republic of China

     

    Item 2(a).Name of Persons Filing:

     

      This statement is filed on behalf of Sio Capital Management, LLC (the “Reporting Person” or “Sio”).
       
      Sio is a registered investment adviser to certain affiliated funds that directly hold the Ordinary Shares to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.

     

    Item 2(b).Address of Principal Business Office:

     

     

    600 Third Avenue, 2nd Floor

    New York, New York 10016

     

    Item 2(c).Citizenship:

     

      Sio is a Delaware limited liability company.   

     

    Item 2(d).Title of Class of Securities:

     

      Ordinary Shares, par value $0.0001 per share, represented by American Depositary Shares (“ADSs”), each representing five Ordinary Shares

     

    Item 2(e).CUSIP Number:

     

     

    38406L103

     

    This is the CUSIP Number for the ADSs, which are traded on the Nasdaq Stock Market. There is no CUSIP Number for the Ordinary Shares.

     

      
     

    CUSIP No. 38406L103 Page 4 of 6

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) x An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    ¨ If this statement is filed pursuant to §240.13d-1(c), check this box.

     

    Item 4.Ownership.

     

    (a) through (c):

     

    The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference.

     

    The Reporting Person also holds 1,370,860 warrants exercisable for Ordinary Shares (the “Warrants”), however the Warrants are subject to a beneficial ownership blocker that precludes their exercise to the extent that, following such exercise, the holder (together with such holder’s affiliates and any other persons acting as a group together) would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the Ordinary Shares outstanding immediately prior to or after giving effect to such exercise. As of December 31, 2023, based on its percentage ownership of Ordinary Shares, the Reporting Person was prohibited from exercising any of the Warrants. The terms of the Warrants state that the Ordinary Shares issuable upon their exercise in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the holder for any purpose, including for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Accordingly, this statement excludes the Warrants.

     

      
     
    CUSIP No. 38406L103 Page 5 of 6

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the Ordinary Shares, check the following : ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

      Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

     

      Not Applicable.

      

    Item 8.Identification and Classification of Members of the Group.

     

      Not Applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

      Not Applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to herein were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

      
     

    CUSIP No. 38406L103 Page 6 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 6, 2024

     

      SIO CAPITAL MANAGEMENT, LLC
       
      By: /s/ Jin W. Lee
      Name:  Jin W. Lee
      Title: Chief Compliance Officer

     

     

     

     

     

    Get the next $GRCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRCL

    DatePrice TargetRatingAnalyst
    11/27/2023Outperform
    Evercore ISI
    10/19/2023$11.00Buy
    Stifel
    3/27/2023$7.00Overweight
    Wells Fargo
    12/8/2022$6.00Buy
    H.C. Wainwright
    9/22/2022$12.00Buy
    Citigroup
    8/18/2022Overweight
    Wells Fargo
    6/1/2022$20.00Overweight
    Cantor Fitzgerald
    4/4/2022$18.00Buy
    BTIG Research
    More analyst ratings

    $GRCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gracell Biotechnologies Acquisition Completed

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ("Parent"), and Grey Wolf Merger Su

      2/22/24 8:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by

      2/20/24 7:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM). "We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR ca

      1/29/24 7:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Gracell Biotechnologies Inc.

      15-12G - Gracell Biotechnologies Inc. (0001826492) (Filer)

      3/4/24 12:22:13 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:31 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Gracell Biotechnologies

      Evercore ISI initiated coverage of Gracell Biotechnologies with a rating of Outperform

      11/27/23 9:23:35 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Gracell Biotechnologies with a new price target

      Stifel initiated coverage of Gracell Biotechnologies with a rating of Buy and set a new price target of $11.00

      10/19/23 7:15:42 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Gracell Biotechnologies with a new price target

      Wells Fargo resumed coverage of Gracell Biotechnologies with a rating of Overweight and set a new price target of $7.00

      3/27/23 8:58:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

      Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO). In this role, Dr. Li will oversee Gracell's clinical development activities, including the advancement of its pipeline of autologous and allogeneic product candidates across the Company's multiple proprie

      8/1/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

      SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including structuring, negotiating and executing of strategic alliances and collaborations.

      7/19/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Financials

    Live finance-specific insights

    See more
    • Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023Presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM); updated data to be reported as an oral presentation at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition (ASH 2023)On track to submit IND filings for planned Phase 1 clinical tr

      11/13/23 7:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time. Conference call and webcast details:Monday, Nov

      10/30/23 8:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLEClosed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash run

      8/14/23 7:15:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 5:01:37 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:20:07 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Gracell Biotechnologies Inc.

      SC 13G - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:00:10 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care